智通财经APP讯,恒瑞医药(600276.SH)发布公告,近日,公司子公司山东盛迪医药有限公司收到国家药品监督管理局(以下简称“国家药监局”)核准签发关于HRS-1301片的《药物临床试验批准通知书》,将于近期开展临床试验。
HRS-1301片是公司自主研发的1类化学药物。临床前研究显示,HRS-1301可有效改善高脂血症。目前全球范围内暂无同类药物获批上市。截至目前,HRS-1301片相关项目累计研发投入约1,836万元。
智通财经APP讯,恒瑞医药(600276.SH)发布公告,近日,公司子公司山东盛迪医药有限公司收到国家药品监督管理局(以下简称“国家药监局”)核准签发关于HRS-1301片的《药物临床试验批准通知书》,将于近期开展临床试验。
HRS-1301片是公司自主研发的1类化学药物。临床前研究显示,HRS-1301可有效改善高脂血症。目前全球范围内暂无同类药物获批上市。截至目前,HRS-1301片相关项目累计研发投入约1,836万元。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.